Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
Rhea-AI Summary
Clearmind Medicine (Nasdaq: CMND) announced that all patients in the second cohort of its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder have completed treatment per protocol.
The second cohort included 6 patients enrolled across multinational sites including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. This milestone follows DSMB approval to continue enrollment and builds on the first cohort’s reported favorable safety profile and preliminary signals of reduced cravings and withdrawal. Topline results from cohort two are expected in the coming months as the study continues to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy.
Positive
- Second cohort completed treatment: 6 patients
- Multinational sites include Johns Hopkins and two Israeli medical centers
- First cohort showed favourable safety and preliminary efficacy signals
Negative
- No topline data released yet for the second cohort
- Small cohort size (6 patients) limits statistical conclusions
News Market Reaction – CMND
On the day this news was published, CMND gained 0.41%, reflecting a mild positive market reaction. Argus tracked a peak move of +26.2% during that session. Argus tracked a trough of -9.0% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $16K to the company's valuation, bringing the market cap to $4M at that time. Trading volume was exceptionally heavy at 7.0x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CMND rose 12.96% while sector peers showed mixed moves; SXTP and KTTA appeared in momentum scans on the upside, but other close peers (e.g., SILO, TTNP) were down, indicating a stock-specific reaction to this trial update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 31 | Listing compliance | Positive | -2.7% | Nasdaq confirms minimum bid price compliance after 10 days above $1. |
| Dec 24 | Year-end review | Positive | -5.8% | Company highlights 2025 clinical progress and IP expansion for CMND-100. |
| Dec 16 | Cohort 2 enrollment | Positive | -3.7% | Completion of second-cohort enrollment in Phase I/IIa CMND-100 trial. |
| Dec 12 | Peer-reviewed review | Positive | +3.6% | Published review highlights MEAI’s potential advantages for AUD treatment. |
| Dec 12 | Equity compliance | Positive | +3.6% | Nasdaq confirms compliance with $2.5M minimum stockholders’ equity rule. |
Recent positive corporate and clinical updates have often seen mixed to negative next-day price reactions, with several clinical-trial milestones showing divergence between upbeat news and short-term performance.
Over the past months, Clearmind has focused on clinical and listing stability milestones. It regained compliance with Nasdaq bid price and stockholders’ equity rules, while repeatedly highlighting progress in its Phase I/IIa trial of CMND-100 for AUD, including site activations, DSMB approval to continue, and second-cohort enrollment. Many of these updates were fundamentally positive yet produced mixed short-term price moves. Today’s successful completion of second-cohort treatment extends this same clinical narrative toward upcoming topline data.
Market Pulse Summary
This announcement reports successful completion of treatment for all six patients in the second cohort of Clearmind’s Phase I/IIa CMND-100 trial for Alcohol Use Disorder, reinforcing prior safety and preliminary efficacy signals. It continues a sequence of milestones including DSMB approval and multinational site activation. With topline data expected in coming months, key factors to watch include safety, tolerability, pharmacokinetics, and early efficacy readouts, alongside the company’s ability to manage capital needs while trading well below its $64.80 52-week high.
Key Terms
Phase I/IIa medical
Alcohol Use Disorder medical
pharmacokinetics medical
Data and Safety Monitoring Board regulatory
AI-generated analysis. Not financial advice.
Vancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).
The second cohort, consisting of six patients recruited across premier clinical sites, including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, has now fully completed the treatment per protocol. This milestone builds on the positive results from the first cohort, which demonstrated a favorable safety profile and preliminary efficacy signals, including reduced cravings and withdrawal symptoms.
“We are pleased to announce the successful completion of treatment in the second cohort, within a month after receiving DSMB approval to continue enrollment, marking continued steady progress in our multinational Phase I/IIa trial,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “This achievement reflects the dedication of our clinical sites and the strong interest in CMND-100 as a potential innovative therapy for AUD, a condition with significant unmet medical needs. We look forward to upcoming data readouts and advancing toward subsequent cohorts.”
The Phase I/IIa trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. Topline results from the second cohort are anticipated in the coming months.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses progress in our multinational Phase I/IIa trial, interest in CMND-100 as a potential innovative therapy for AUD and advancing toward subsequent cohorts. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What did Clearmind (CMND) announce on January 14, 2026 about CMND-100?
How many patients were in the second cohort of the CMND-100 Phase I/IIa trial?
Which clinical sites participated in Clearmind CMND-100 cohort two?
When will Clearmind (CMND) report topline results for the second cohort?
What did the first cohort results indicate for CMND-100 in AUD?
Does the completion of cohort two mean CMND-100 is approved for AUD?
